Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

Aug 28, 04:24 PM
Headliner
Share
Subscribe

FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major biopharma deals, and Israel Ortiz makes the case for preventive maintenance in manufacturing.

Share
Subscribe
Next
Pharmaceutical Executive Daily: President Trump Planning New Medicaid Drug-Pricing Deals
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Key Findings of the NIAGARA and HIMALAYA Trials
by Pharmaceutical Executive